Literature DB >> 22761205

Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.

Andreas Pircher1, Eva Maria Gassner, Michael Steurer, Dominik Wolf.   

Abstract

The optimal management of patients with diffuse large B cell lymphoma relapsing after autologous haematopoetic stem cell transplantation (HCT) is difficult and no standard treatment has been defined. The authors here report the case of a rituximab-naive patient who relapsed after HCT and was cured with rituximab monotherapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22761205      PMCID： PMC3391410          DOI： 10.1136/bcr.02.2012.5856

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  12 in total

1.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Authors:  Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glass; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler
Journal:  Lancet Oncol       Date:  2008-01-15       Impact factor: 41.316

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.

Authors:  Dorothy Pan; Craig H Moskowitz; Andrew D Zelenetz; David Straus; Tarun Kewalaramani; Ariela Noy; Jing Qin; Julie Teruya-Feldstein; Carol S Portlock
Journal:  Cancer J       Date:  2002 Sep-Oct       Impact factor: 3.360

4.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

5.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

Authors:  B Coiffier; C Haioun; N Ketterer; A Engert; H Tilly; D Ma; P Johnson; A Lister; M Feuring-Buske; J A Radford; R Capdeville; V Diehl; F Reyes
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

6.  Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

Authors:  Kathrin Wanner; Susanne Hipp; Madlene Oelsner; Ingo Ringshausen; Christian Bogner; Christian Peschel; Thomas Decker
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

7.  Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

Authors:  T A Davis; A J Grillo-López; C A White; P McLaughlin; M S Czuczman; B K Link; D G Maloney; R L Weaver; J Rosenberg; R Levy
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

8.  Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy.

Authors:  Eric Robach; Celalettin Ustun; Andre Kallab; Russel E Burgess; Anand P Jillella
Journal:  Leuk Lymphoma       Date:  2002-11

9.  Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

Authors:  Ali R Jazirehi; Mario I Vega; Benjamin Bonavida
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.

Authors:  Edo Vellenga; Wim L J van Putten; Mars B van 't Veer; Josée M Zijlstra; Willem E Fibbe; Marinus H J van Oers; Leo F Verdonck; Pierre W Wijermans; Gustaaf W van Imhoff; Pieternella J Lugtenburg; Peter C Huijgens
Journal:  Blood       Date:  2007-10-30       Impact factor: 22.113
View more
  1 in total

Review 1.  Management of relapsed-refractory diffuse large B cell lymphoma.

Authors:  Lalit S Raut; Prantar P Chakrabarti
Journal:  South Asian J Cancer       Date:  2014-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.